Article

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia

Université Paris-Sud 11, Orsay, Île-de-France, France
Blood (Impact Factor: 9.78). 04/2007; 109(5):2202-4. DOI: 10.1182/blood-2006-09-045963
Source: PubMed

ABSTRACT Activation of tyrosine kinase genes is a frequent event in human hematologic malignancies. Because gene activation could be associated with gene dysregulation, we attempted to screen for activating gene mutation based on high-level gene expression. We focused our study on the Janus kinase 2 (JAK2) gene in 90 cases of acute leukemia. This strategy led to the identification of a novel JAK2-acquired mutation in a patient with Down syndrome (DS) with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This mutation involves a 5-amino acid deletion within the JH2 pseudokinase domain (JAK2DeltaIREED). Expression of JAK2DeltaIREED in Ba/F3 cells induced constitutive activation of the JAK-STAT pathway and growth factor-independent cell proliferation. These results highlight the JAK2 pseudokinase domain as an oncogenic hot spot and indicate that activation of the JAK-STAT pathway may contribute to lymphoid malignancies and hematologic disorders observed in children with DS.

0 Followers
 · 
135 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Originally shown to promote the growth and activation of B cells, thymic stromal lymphopoietin (TSLP) is now known to have wide-ranging effects on both hematopoietic and nonhematopoietic cell lineages. These include dendritic cells, basophils, mast cells, B cells, epithelial cells, and CD4(+), CD8(+), and NK T cells. Although TSLP's role in the promotion of Th2 responses has been studied extensively in the context of lung- and skin-specific allergic disorders, it is becoming increasingly clear that TSLP may impact multiple disease states within multiple organ systems. This review highlights recent advances in the understanding of the surprising role of TSLP in the control of a variety of cancers, both solid tumors and leukemia, in which the TSLP/TSLP receptor axis was shown to be an important regulator.
    The Journal of Immunology 11/2014; 193(9):4283-4288. DOI:10.4049/jimmunol.1400864 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The acquisition of growth signal self-sufficiency is one of the hallmarks of cancer. We previously reported that the murine IL-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the JAK-STAT pathway. Here, we show that this transforming event results from activating mutations either in JAK1, JAK3 or in both kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activation, and that their coexpression further increases this activation. The proliferation of growth factor-independent TS1 clones can be efficiently blocked by JAK inhibitors such as ruxolitinib or CMP6 in short term assays. However, resistant clones occur upon long term culture in the presence of inhibitors. Surprisingly, resistance to CMP6 was not caused by the acquisition of secondary mutations in the ATP-binding pocket of the JAK mutant. Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK3, whereas, cells that originally showed a JAK3-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK1. These observations underline the cooperation between JAK1 and JAK3 mutants in T cell transformation, and represent a new mechanism of acquisition of resistance against JAK inhibitors.
    Blood 10/2014; 124(26). DOI:10.1182/blood-2014-05-576652 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Jak2 is involved in cytokine growth factor stimulated signal transduction but the mechanism of its activation is largely unknown. Here, we investigated Jak2 activation in a normal hematopoietic cell line, 32D mouse myeloid cells. The BiFC studies showed that c-Abl formed a stable complex with Jak2 in live cells. Co-IP results showed that c-Abl bound to βc chain of IL-3/IL-5/GM-CSF receptors. The kinase activities of both c-Abl and Jak2 were stimulated by IL-3 in 32D cells. Decreasing c-Abl protein expression in 32D cells by inducible shRNA decreased Jak2 activity and resulted in the failure of Jak2 activation in response to IL-3. Treatment of IL-3 and serum-starved 32D cells with 1 μM IM inhibited IL-3 stimulated kinase activities of both c-Abl and Jak2. In addition, the kinase-deficient Bcr-Abl mutant (p210K1172R) was defective for activation of Jak2 in 32D cells and impaired IL-3 independent growth, which was rescued by overexpression of c-Abl (+Abl). IL-3 efficiently inhibited apoptosis of 32Dp210K/R+Abl cells induced by IM but not Jak2 kinase inhibitor TG101209. In summary, our findings provide evidence that the kinase function of c-Abl and its C-terminal CT-4 region are crucial for its interaction with Jak2 and its activation. c-Abl kinase activity induced by IL-3 is required for IL-3 stimulated Jak2 activation. Our findings reveal a novel regulatory role of c-Abl in Jak2 activation induced by IL-3 cytokine growth factor in 32D hematopoietic cells.
    Journal of Biological Chemistry 06/2014; 289(31). DOI:10.1074/jbc.M114.554501 · 4.60 Impact Factor

Preview

Download
1 Download